- Details
- Description
-
Packaging Size1bottle/Box
-
Strength60mg
-
CompositonDisitamab vedotin
-
TreatmentGastric cancer and Urothelial cancer
-
FormInjection
-
Brand爱地希
-
Quantity Unit60mg*1vail/bottle
-
ManufacturerRemeGen.,China
About Disitamab Vedotin
An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of trastuzumab vedotin, the trastuzumab moiety targets and binds to HER2 on the surface of tumor cells. Following internalization, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.
- Disitamab Vedotin sold under the brand name 爱地希® in china.
Disitamab Vedotin is the first Chinese ADC drug to be dually recognized as a breakthrough therapy by the FDA of US and NMPA of China. Its gastric cancer and urothelial cancer indications were approved for marketing by NMPA of China in June 2021, and December 2021.
